Singular Genomics Systems, Inc.

Symbol: OMIC

NASDAQ

0.4479

USD

Market price today

  • -0.3530

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 33.18M

    MRK Cap

  • 0.00%

    DIV Yield

Singular Genomics Systems, Inc. (OMIC) Financial Statements

On the chart you can see the default numbers in dynamics for Singular Genomics Systems, Inc. (OMIC). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Singular Genomics Systems, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM20232022202120202019

balance-sheet.row.cash-and-short-term-investments

0173.9244.6339.2
26.9
46.2

balance-sheet.row.short-term-investments

0157.7170.3138.2
15.2
40.7

balance-sheet.row.net-receivables

01.60.91.1
0
0

balance-sheet.row.inventory

013.618.23
0
0

balance-sheet.row.other-current-assets

01.54.74.5
0.7
0.3

balance-sheet.row.total-current-assets

0192.2268.4347.8
27.6
46.5

balance-sheet.row.property-plant-equipment-net

071.556.76.1
2.4
1.6

balance-sheet.row.goodwill

0000
0
0

balance-sheet.row.intangible-assets

0000
0
0

balance-sheet.row.goodwill-and-intangible-assets

0-16.3-14.90
0
0

balance-sheet.row.long-term-investments

00.61.70.7
0.5
0

balance-sheet.row.tax-assets

015.713.20
0
0

balance-sheet.row.other-non-current-assets

01.82.91.1
0.1
0.1

balance-sheet.row.total-non-current-assets

073.259.57.9
2.9
1.7

balance-sheet.row.other-assets

0000
0
0

balance-sheet.row.total-assets

0265.5328355.6
30.5
48.2

balance-sheet.row.account-payables

02.63.12.3
0.4
0.6

balance-sheet.row.short-term-debt

07.86.30
0.9
0

balance-sheet.row.tax-payables

0000
0
0

balance-sheet.row.long-term-debt-total

067.552.59.9
8.5
2.4

Deferred Revenue Non Current

00.30.10
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-

balance-sheet.row.other-current-liab

01.94.74.4
0.7
0.6

balance-sheet.row.total-non-current-liabilities

068.253.512.7
78.4
71.8

balance-sheet.row.other-liabilities

0000
0
0

balance-sheet.row.capital-lease-obligations

066.448.80
0
0

balance-sheet.row.total-liab

086.567.719.5
82.1
72.9

balance-sheet.row.preferred-stock

000355.6
69.2
69.2

balance-sheet.row.common-stock

0000
0
0

balance-sheet.row.retained-earnings

0-337.6-242.8-151.9
-53.1
-25.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

00.2-0.8-0.1
0
0

balance-sheet.row.other-total-stockholders-equity

0516.4503.9132.6
-67.6
-68.8

balance-sheet.row.total-stockholders-equity

0179260.3336.2
-51.6
-24.7

balance-sheet.row.total-liabilities-and-stockholders-equity

0265.5328355.6
30.5
48.2

balance-sheet.row.minority-interest

0000
0
0

balance-sheet.row.total-equity

0179260.3336.2
-51.6
-24.7

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-

Total Investments

0157.7170.3138.2
15.2
40.7

balance-sheet.row.total-debt

075.358.89.9
9.4
2.4

balance-sheet.row.net-debt

059.1-15.4-191.1
-2.3
-3.1

Cash Flow Statement

The financial landscape of Singular Genomics Systems, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019

cash-flows.row.net-income

0-94.8-90.9-98.8
-27.9
-12.3

cash-flows.row.depreciation-and-amortization

07.261.1
0.6
0.3

cash-flows.row.deferred-income-tax

00.804.1
0.3
0

cash-flows.row.stock-based-compensation

011.413.79.2
1.1
0.2

cash-flows.row.change-in-working-capital

0-2.2-16.8-2.9
0.9
0.4

cash-flows.row.account-receivables

00.3-0.90
0
0

cash-flows.row.inventory

0-3.5-13.50
0
0

cash-flows.row.account-payables

00.3-1.21.9
-0.1
0.2

cash-flows.row.other-working-capital

02.9-1.2-4.8
1
0.2

cash-flows.row.other-non-cash-items

040.935.5
0.2
0

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-1-6-4.9
-1.4
-0.8

cash-flows.row.acquisitions-net

0033.5126
-25.4
30.7

cash-flows.row.purchases-of-investments

0-183.6-174.7-195.7
-6.1
-42.7

cash-flows.row.sales-maturities-of-investments

0198.4141.269.7
31.5
12

cash-flows.row.other-investing-activites

00-33.5-126
25.4
-30.7

cash-flows.row.net-cash-used-for-investing-activites

013.8-39.6-130.9
24
-31.5

cash-flows.row.debt-repayment

000-10.4
-7.5
-2.5

cash-flows.row.common-stock-issued

000.2240.8
0
0

cash-flows.row.common-stock-repurchased

00-0.53.6
0
0

cash-flows.row.dividends-paid

000-3.6
-7.5
-2.4

cash-flows.row.other-financing-activites

00.71.2141.8
22.5
52.2

cash-flows.row.net-cash-used-provided-by-financing-activities

00.70.9372.1
7.5
47.3

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0

cash-flows.row.net-change-in-cash

0-59.1-125.8189.6
6.6
4.4

cash-flows.row.cash-at-end-of-period

016.876201.7
12.2
5.5

cash-flows.row.cash-at-beginning-of-period

076201.712.2
5.5
1.1

cash-flows.row.operating-cash-flow

0-73.6-87.1-51.7
-24.9
-11.4

cash-flows.row.capital-expenditure

0-1-6-4.9
-1.4
-0.8

cash-flows.row.free-cash-flow

0-74.6-93.1-56.6
-26.3
-12.2

Income Statement Row

Singular Genomics Systems, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of OMIC is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019

income-statement-row.row.total-revenue

02.90.80
0
0

income-statement-row.row.cost-of-revenue

03.50.81.1
0.6
0.3

income-statement-row.row.gross-profit

0-0.60-1.1
-0.6
-0.3

income-statement-row.row.gross-profit-ratio

0000
0
0

income-statement-row.row.research-development

0---
-
-

income-statement-row.row.selling-general-administrative

0---
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-

income-statement-row.row.other-expenses

0000.4
0
0

income-statement-row.row.operating-expenses

0102.293.561.3
27.5
12.8

income-statement-row.row.cost-and-expenses

0105.794.361.3
27.5
12.8

income-statement-row.row.interest-income

09.13.40.3
0.5
0.5

income-statement-row.row.interest-expense

01.10.80.8
0.7
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-

income-statement-row.row.total-other-income-expensenet

082.6-37.5
-0.4
0.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-

income-statement-row.row.other-operating-expenses

0000.4
0
0

income-statement-row.row.total-operating-expenses

082.6-37.5
-0.4
0.4

income-statement-row.row.interest-expense

01.10.80.8
0.7
0

income-statement-row.row.depreciation-and-amortization

07.23.40.7
1.1
0.8

income-statement-row.row.ebitda-caps

0---
-
-

income-statement-row.row.operating-income

0-102.8-93.5-61.3
-27.5
-12.8

income-statement-row.row.income-before-tax

0-94.8-90.9-98.8
-27.9
-12.3

income-statement-row.row.income-tax-expense

09.1-2.60.1
0.7
0

income-statement-row.row.net-income

0-94.8-88.3-98.9
-28.7
-12.3

Frequently Asked Question

What is Singular Genomics Systems, Inc. (OMIC) total assets?

Singular Genomics Systems, Inc. (OMIC) total assets is 265467000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is -0.192.

What is company free cash flow?

The free cash flow is -1.014.

What is enterprise net profit margin?

The net profit margin is -32.063.

What is firm total revenue?

The total revenue is -35.315.

What is Singular Genomics Systems, Inc. (OMIC) net profit (net income)?

The net profit (net income) is -94820000.000.

What is firm total debt?

The total debt is 75288000.000.

What is operating expences number?

The operating expences are 102243000.000.

What is company cash figure?

Enretprise cash is 0.000.